Table 1.

Japanese cohort characteristics and clinical outcome: DFS and OS

DFSOS
Characteristicsn (%)Median DFS, y (95% CI)HR (95% CI)PaMedian OS, y (95% CI)HR (95% CI)Pa
Age, y0.001<0.001
 <6565 (38%)20.1b (4.8–20.1b)1 (Reference)20.1b (5.7–20.1b)1 (Reference)
 65–7460 (36%)9.0b (1.7–9.0b)1.59 (0.92–2.75)4.3 (2.8–9.0b)1.97 (1.08–3.60)
 ≥7544 (26%)1.7 (1.2–2.5)2.67 (1.53–4.65)2.1 (1.5–2.8)4.04 (2.18–7.49)
Sex0.980.50
 Male109 (64%)4.8 (2.0–20.1b)1 (Reference)5.7 (3.4–20.1b)1 (Reference)
 Female60 (36%)16.1b (1.9–16.1b)1.01 (0.64–1.59)3.9 (2.7–16.1b)1.18 (0.73–1.91)
Stage<0.001<0.001
 IB28 (16%)20.1b1 (Reference)20.1b1 (Reference)
 II53 (31%)16.1b (2.4–16.1b)4.56 (1.38–15.11)16.1b (3.4–16.1b)3.96 (1.20–13.12)
 III60 (36%)2.5 (2.0–6.3b)6.45 (2.00–20.80)4.3 (2.7–6.3b)5.27 (1.63–17.03)
 IV28 (16%)0.7 (0.4–1.6)17.30 (5.22–57.29)1.2 (0.8–2.7)15.71 (4.72–52.27)
Tumor stage0.001
 T1d12 (7%)0.003
 T2d66 (39%)20.1b1 (Reference)20.1b (4.3–20.1b)1 (Reference)
 T3e88 (52%)2.0 (1.6–4.8)2.09 (1.31–3.32)3.4 (2.2–16.1b)2.06 (1.26–3.37)
 T4e3 (2%)
N<0.0010.001
 N036 (21%)20.1b1 (Reference)20.1b1 (Reference)
 N185 (50%)15.4 (2.2–15.4b)2.00 (0.97–4.13)15.4 (3.4–15.4b)1.75 (0.84–3.65)
 N233 (20%)2.2 (1.6–4.8)3.16 (1.45–6.90)3.4 (2.3–5.7)2.70 (1.21–6.01)
 N315 (9%)1.3 (0.6–2.2)5.95 (2.53–14.00)2.3 (0.4–3.1)4.74 (1.94–11.57)
Tumor site0.230.19
 Lower55 (32%)2.3 (1.6–16.1b)1 (Reference)16.1b (2.1–16.1b)1 (Reference)
 Middle59 (35%)20.1b (2.0–20.1b)0.87 (0.51–1.46)4.1 (3.0–20.1b)0.89 (0.51–1.54)
 Upper49 (29%)15.2b (3.0–15.2b)0.69 (0.38–1.23)5.7 (3.9–15.2b)0.66 (0.35–1.22)
 GEJ3 (2%)2.2 (1.1–2.3)1.99 (0.60–6.58)2.8 (1.4–2.9b)2.28 (0.68–7.61)
 UML3 (2%)0.9 (0.9–2.0)2.22 (0.52–9.44)4.0bc
Tumor differentiation0.670.63
 Well–moderate68 (40%)20.1b (1.9–20.1b)1 (Reference)20.1b (3.4–20.1b)1 (Reference)
 Poor101 (60%)3.0 (2.2–7.2b)1.10 (0.70–1.74)4.3 (3.0–7.2b)1.12 (0.69–1.82)
PS<0.001<0.001
 ECOG 0157 (93%)20.1b (2.9–20.1b)1 (Reference)20.1b (3.9–20.1b)1 (Reference)
 ECOG 112 (7%)1.2 (0.3–1.9)3.41 (1.79–6.47)1.2 (0.2–2.3)4.75 (2.45–9.22)
Chemotherapy0.0080.067
 No60 (36%)20.1b1 (Reference)20. 1b1 (Reference)
 Yes109 (64%)2.3 (1.9–4.8)1.97 (1.18–3.30)3.4 (2.8–16.1b)1.62 (0.96–2.75)

Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status; UML, upper–middle–lower.

  • aOn the basis of log-rank test.

  • bEstimates were not reached.

  • cNo events occurred and estimates were not obtained.

  • d,eGrouped together for the estimates of HR.